Lupus miliaris disseminatus faciei successfully treated with tranilast: Report of two cases

被引:10
作者
Koike, Yumi [1 ]
Hatamochi, Atsushi [1 ]
Koyano, Satomi [1 ]
Namikawa, Hiromi [1 ]
Hamasaki, Yoichiro [1 ]
Yamazaki, Soji [1 ]
机构
[1] Dokkyo Med Univ, Dept Dermatol, Sch Med, Mibu, Tochigi 3210293, Japan
关键词
lupus miliaris disseminates faciei; tranilast; treatment; MATRIX ACCUMULATION; GROWTH; CANCER;
D O I
10.1111/j.1346-8138.2010.01116.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We report two cases of lupus miliaris disseminatus faciei (LMDF) in which oral tranilast was effective. In case 1, the patient was a 33-year-old woman who had developed pale red papules on her face, especially around her eyes and lower jaw, approximately 7 months previously. Examination of a skin biopsy specimen revealed epithelioid cell granulomas accompanied by caseous necrosis, and a diagnosis of LMDF was made. The patient was treated successively with azithromycin, roxithromycin and minocycline hydrochloride, but there was no improvement. When we tried oral tranilast therapy, flattening of the papules was observed 2 weeks after the start of treatment, and by 1 month the papules had almost disappeared. In case 2, the patient was a 39-year-old man who had broken out in erythematous papules on both upper and lower eyelids, with some accompanied by scaling, 2 years before the initial examination. Pathological specimen revealed epithelioid cell granulomas accompanied by caseous necrosis, and a diagnosis of LMDF was made. There was no improvement when treated orally with minocycline hydrochloride or doxycycline hydrochloride, and treatment was switched to oral tranilast therapy. After 1 month of treatment, the papules had almost disappeared. We concluded that oral tranilast therapy should be tried as a treatment for intractable LMDF.
引用
收藏
页码:588 / 592
页数:5
相关论文
共 21 条
[1]   PHARMACOLOGICAL PROPERTIES OF N-(3',4'-DIMETHOXYCINNAMOYL) ANTHRANILIC ACID (N-5'), A NEW ANTI-ATOPIC AGENT [J].
AZUMA, H ;
BANNO, K ;
YOSHIMURA, T .
BRITISH JOURNAL OF PHARMACOLOGY, 1976, 58 (04) :483-488
[2]  
BERTH JJ, 2004, ROOKS TXB DERMATOLOG, V3
[3]   Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes [J].
Bonnet, F ;
Cao, Z ;
Cooper, ME ;
Cox, AJ ;
Kelly, DJ ;
Gilbert, RE .
DIABETES & METABOLISM, 2003, 29 (04) :386-392
[4]   Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells [J].
Fukuyama, J ;
Miyazawa, K ;
Hamano, S ;
Ujiie, A .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1996, 74 (01) :80-84
[5]  
HERVE B, 2001, ARCH DERMATOL, V137, P69
[6]  
Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156
[7]   Successful treatment of granulomatous cheilitis with roxithromycin [J].
Ishiguro, Emiko ;
Hatamochi, Atsushi ;
Hamasaki, Yoichiro ;
Ishikawa, Satoko ;
Yamazaki, Soji .
JOURNAL OF DERMATOLOGY, 2008, 35 (09) :598-600
[8]   A case of confluent and reticulated papillomatosis that successfully responded to roxithromycin [J].
Ito, Sachie ;
Hatamochi, Atsushi ;
Yamazaki, Soji .
JOURNAL OF DERMATOLOGY, 2006, 33 (01) :71-72
[9]   Tranilast Inhibits Hormone Refractory Prostate Cancer Cell Proliferation and Suppresses Transforming Growth Factor β1-Associated Osteoblastic Changes [J].
Izumi, Kouji ;
Mizokami, Atsushi ;
Li, You Qiang ;
Narimoto, Kazutaka ;
Sugimoto, Kazuhiro ;
Kadono, Yoshifumi ;
Kitagawa, Yasuhide ;
Konaka, Hiroyuki ;
Koh, Eitetsu ;
Keller, Evan T. ;
Namiki, Mikio .
PROSTATE, 2009, 69 (11) :1222-1234
[10]  
KATO T, 1996, J DERMATOL, V23, P335